Full Press Release Details
BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510.
BBIO
BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510
Key Takeaway: BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510